- In patients with recurrent ovarian cancer, daily cabozantinib yields PFS similar to weekly paclitaxel, but worse OS, event-free survival (EFS), and overall response rate (ORR).
- Gastrointestinal toxicities were more frequent with cabozantinib.
Why this matters
- Trials evaluating combination treatment with cabozantinib are ongoing.
- Phase 2 NRG Oncology/Gynecologic Oncology Group study: 111 patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma were randomly assigned 1:1 to daily 60 mg cabozantinib or weekly paclitaxel.
- Primary endpoint: PFS.
- Funding: National Cancer Institute.
- Median follow-up time was 13.9 months for cabozantinib and 14.5 months for paclitaxel group.
- Median PFS was not significantly different between cabozantinib and paclitaxel (5.3 vs 5.5 months; HR, 1.1; P=.64).
- Cabozantinib was associated with significantly worse median OS (19.4 months vs not reached; HR, 2.27; P=.04) and EFS (3.5 vs 5.0 months; HR, 1.81; P=.01) vs paclitaxel.
- ORR was lower for cabozantinib compared with weekly paclitaxel (7% vs 24.1%).
- Gastrointestinal toxicities (nausea, diarrhea, and abdominal pain) were more frequent with cabozantinib.
- Open-label design.